Insmed Inc Drug Patent Portfolio
Insmed Inc owns 1 orange book drug protected by 13 US patents Given below is the list of Insmed Inc's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10251900 | Methods for treating pulmonary non-tuberculous mycobacterial infections | 15 May, 2035 | Active |
| US10751355 | Methods for treating pulmonary non-tuberculous mycobacterial infections | 15 May, 2035 | Active |
| US11446318 | Methods for treating pulmonary non-tuberculous mycobacterial infections | 15 May, 2035 | Active |
| US12016873 | Methods for treating pulmonary non-tuberculous mycobacterial infections | 15 May, 2035 | Active |
| US9895385 | Methods for treating pulmonary non-tuberculous mycobacterial infections | 15 May, 2035 | Active |
| US9566234 | Systems for treating pulmonary infections | 18 Jan, 2034 | Active |
| US8226975 | Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof | 15 Aug, 2028 | Active |
| US8632804 | Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof | 05 Dec, 2026 | Active |
| US8642075 | Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof | 05 Dec, 2026 | Active |
| US8679532 | Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof | 05 Dec, 2026 | Active |
| US7718189 | Sustained release of antiinfectives | 06 Jun, 2025 | Active |
| US8802137 | Sustained release of antiinfectives | 08 Apr, 2024 | Expired |
| US9827317 | Sustained release of antiinfectives | 08 Apr, 2024 | Expired |
Latest Legal Activities on Insmed Inc's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Insmed Inc.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Notice of Final Determination- Ineligible | 07 Feb, 2024 | US8226975 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 24 Jan, 2024 | US10751355 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 19 Dec, 2023 | US8226975 |
| Post Issue Communication - Certificate of Correction | 12 Oct, 2022 | US9566234 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 20 Sep, 2022 | US11446318 |
|
Recordation of Patent Grant Mailed
Critical
| 20 Sep, 2022 | US11446318 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 20 Sep, 2022 | US10251900 |
|
Email Notification
Critical
| 01 Sep, 2022 | US11446318 |
|
Issue Notification Mailed
Critical
| 31 Aug, 2022 | US11446318 |
|
Application Is Considered Ready for Issue
Critical
| 23 Aug, 2022 | US11446318 |
| Dispatch to FDC | 23 Aug, 2022 | US11446318 |
| Printer Rush- No mailing | 19 Aug, 2022 | US11446318 |
|
Information Disclosure Statement considered
Critical
| 19 Aug, 2022 | US11446318 |
|
Pubs Case Remand to TC
Critical
| 08 Aug, 2022 | US11446318 |
|
Information Disclosure Statement (IDS) Filed
Critical
| 05 Aug, 2022 | US11446318 |
Insmed Inc Drug Patents' Oppositions Filed in EPO
Insmed Inc drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jun 04, 2014, by Generics [Uk] Limited. This opposition was filed on patent number EP06787716A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP11159754A | Feb, 2016 | Generics [UK] Limited | Revoked |
| EP06787716A | Jun, 2014 | Generics [UK] Limited | Patent maintained as amended |
Insmed Inc's Family Patents
Insmed Inc drugs have patent protection in a total of 29 countries. It's US patent count contributes only to 31.2% of its total global patent coverage. 4 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Insmed Inc Drug List
Given below is the complete list of Insmed Inc's drugs and the patents protecting them.
1. Arikayce Kit
Arikayce Kit is protected by 13 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10251900 | Methods for treating pulmonary non-tuberculous mycobacterial infections |
15 May, 2035
(10 years from now)
| Active |
| US10751355 | Methods for treating pulmonary non-tuberculous mycobacterial infections |
15 May, 2035
(10 years from now)
| Active |
| US11446318 | Methods for treating pulmonary non-tuberculous mycobacterial infections |
15 May, 2035
(10 years from now)
| Active |
| US12016873 | Methods for treating pulmonary non-tuberculous mycobacterial infections |
15 May, 2035
(10 years from now)
| Active |
| US9895385 | Methods for treating pulmonary non-tuberculous mycobacterial infections |
15 May, 2035
(10 years from now)
| Active |
| US9566234 | Systems for treating pulmonary infections |
18 Jan, 2034
(9 years from now)
| Active |
| US8226975 | Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof |
15 Aug, 2028
(3 years from now)
| Active |
| US8632804 | Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof |
05 Dec, 2026
(1 year, 11 months from now)
| Active |
| US8642075 | Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof |
05 Dec, 2026
(1 year, 11 months from now)
| Active |
| US8679532 | Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof |
05 Dec, 2026
(1 year, 11 months from now)
| Active |
| US7718189 | Sustained release of antiinfectives |
06 Jun, 2025
(5 months from now)
| Active |
| US8802137 | Sustained release of antiinfectives |
08 Apr, 2024
(8 months ago)
| Expired |
| US9827317 | Sustained release of antiinfectives |
08 Apr, 2024
(8 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Arikayce Kit's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List